Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck pleased to launch Tredaptive in UK

Merck pleased to launch Tredaptive in UK

21st May 2009

Merck is pleased to start launching Tredaptive (ER niacin/laropiprant) in the UK later this year, it has stated.

Intended to help patients with mixed dyslipidemia and primary hypercholesterolemia, the lipid-modifying therapy will also be marketed in Mexico and Germany by the third quarter of 2009.

Currently, the therapy has been permitted in 39 countries and is known under the trademark Cordaptive in some places.

Dr Luciano Rossetti is the senior vice-president and franchise head of the company’s atherosclerosis and cardiovascular division.

He commented: “Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care.”

Earlier this year, the company responded to the Food and Drug Administration’s review of Singulair, a treatment for asthma and allergic rhinitis.

The regulatory body requested the medication be evaluated as it had been linked with mood changes and suicidal feelings in some patients.

Merck asserted safety was of great importance to the business and it continually reviews post-marketing reports.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.